Synthetic fibronectin fragments as inhibitors of retroviral infection

• US 5,545,620 A
• Filed: 08/16/1994
• Issued: 08/13/1996
• Est. Priority Date: 01/19/1993
• Status: Expired due to Term

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America), Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America), Regents of The University of Minnesota (University of Minnesota)
• Inventors: Furcht, Leo T., Wahl, Sharon M., McCarthy, James B.
• Primary Examiner(s): Kim, Kay K. A.
• Application Number:
  US08/291,349
• Time in Patent Office: 728 Days
• Field of Search: 530/326, 530/327, 530/328, 530/345, 530/403, 530/408, 530/409, 530/405, 530/404, 530/324, 530/325, 530/367, 516/12-16, 516/8, 516/21, 435/236
• US Class Current: 514/3.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

The invention includes methods for inhibiting retroviral infections such as HIV. The methods of this invention involve the use of certain fragments of fibronectin and such fragments conjugated to carrier molecules such as ovalbumin to inhibit retroviral infections. The invention also includes novel proteins which comprise fibronectin fragments covalently linked to carrier proteins.

Claims

1. A method for inhibiting HIV-1 virus infection of mammalian cells comprising contacting the cells with an effective inhibiting amount of a fibronectin fragment or carrier molecule conjugates thereof, where the fibronectin fragment amino acid sequence is selected from the group consisting of:

YEKPGSPPRE WPRPRPGV (FN1;

SEQ ID NO;

1), KNNQKSEPLI GRKKT (FN2;

SEQ ID NO;

2), YRVRVTPKEK TGPMKE (FN3;

SEQ ID NO;

3), SPPRRARVT (FN4;

SEQ ID NO;

4), and WQPPRARI (FN5;

SEQ ID NO;

5). D[P]ELPQLVTLP HPNLHGPEIL DVPST (FN6;

SEQ ID NO;

6), and ITVYAVTGRG DSPASSKPISI (FN7;

SEQ ID NO;

7).

2. The method of claim 1 wherein zidovudine (AZT), dideoxyinosine, dideoxycytosinene, or dideoxycytosine is used in combination with the fibronectin fragment or carrier molecule conjugate thereof.

3. A method according to claim 1 wherein the carrier molecule is ovalbumin.